Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDUA | P35475 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.31 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.31 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PYGB | P11216 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14519956 | 1.00 | IDUA (0.33) | IDUAADORA3METTL3CAPN9CAPN1 | |
| SCHEMBL5810720 | 0.88 | PYGB (0.41) | IDUAPYGB | |
| SCHEMBL12110848 | 0.84 | ADORA3 (0.43) | ADORA3CAPN9CAPN1CTSBMAPK1 | |
| SCHEMBL31429684 | 0.76 | GFPT1 (0.36) | IDUA | |
| SCHEMBL14189087 | 0.74 | ADORA2A (0.41) | ADORA3MAPK1 | |
| SCHEMBL20873287 | 0.73 | CYP1A2 (0.34) | — | |
| SCHEMBL23740489 | 0.72 | EPHX2 (0.33) | METTL3 | |
| SCHEMBL13944665 | 0.72 | EPHX2 (0.33) | METTL3 | |
| SCHEMBL14172403 | 0.72 | EPHX2 (0.33) | METTL3 | |
| SCHEMBL26292937 | 0.72 | HSP90AA1 (0.30) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208611-B2 | Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use | XENOPORT, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060205677-A1 | Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use | XENOPORT, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205677-A1 | Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use | TYMP, TOP1, TOP2A | IDUA 2701/4885ADORA3 3715/4885METTL3 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.